Neuraxpharm Group
Austria – Deutsh
Belgium РFran̤ais
Belgium – Vlaams
Czech Republic – Czech
France РFran̤ais
Germany – Deutsh
Greece – Eλληνικά
Hungary – Hungarian
Ireland – English
Italy – Italiano
Netherlands – Nederlands
Poland – Polski
Portugal РPortugu̻s
Slovakia – Slovenský
Spain РEspa̱ol
Sweden – Svenska
Switzerland – Deutsh
Switzerland РFran̤ais
Switzerland – Italiano
United Kingdom – English

News

Announcement
- 10.10.2024

Neuraxpharm supports World Mental Health Day

Press release
- 01.10.2024

Neuraxpharm expands operations into the Middle East

Press release
- 23.09.2024

Neuraxpharm Receives Positive CHMP Opinion for the Extension of Indication of Epilepsy Treatment Buccolam® to Adults

Announcement
- 20.09.2024

Neuraxpharm and partner TG Therapeutics present at the world’s largest Multiple Sclerosis meeting, ECTRIMS 2024

Press release
- 18.09.2024

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Announcement
- 31.07.2024

Neuraxpharm will be using Veeva to advance its quality operations

Press release
- 11.06.2024

Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain

Announcement
- 05.06.2024

Neuraxpharm attends Bio International Convention 2024

Press release
- 31.05.2024

Update on Regulatory Review of NEZGLYAL® (leriglitazone) in the EU

Announcement
- 24.05.2024

Neuraxpharm Advocates World Schizophrenia Awareness Day

View more

Media Enquiries

If you are a journalist with a media enquiry, please contact the Neuraxpharm media office by filling the contact form.

CNS

Neuraxpharm

Support

Linkedin Youtube

Join our mailing list

Get the latest updates from the Neuraxpharm.